New Roche Combo Cuts Lymphoma Progression Risk by 59%

A new Roche treatment combination has moved a step closer to the market after the US Food and Drug Administration (FDA) accepted the company’s supplemental Biologics License Application (sBLA).

The new Roche combo combines Lunsumio VELO and Polivy for adults with relapsed or refractory large B-cell lymphoma (LBCL), offering a potential chemotherapy-free treatment option for patients facing limited choices after initial therapy.

The FDA is expected to make its decision by February 9, 2027. The filing covers Lunsumio VELO (mosunetuzumab) in a subcutaneous formulation together with Polivy (polatuzumab vedotin). Within the first 100 words of Roche’s announcement, the company highlighted that the new Roche combo could help address a major unmet need in lymphoma care by providing an outpatient-ready treatment option.

Phase III Study Shows Strong Survival Benefit

The FDA submission is supported by data from the Phase III SUNMO study, which demonstrated significant clinical benefits compared with the current standard treatment regimen of MabThera/Rituxan (rituximab) plus gemcitabine and oxaliplatin (R-GemOx).

Key findings from the SUNMO trial include:

• The combination reduced the risk of disease progression or death by 59%.
• The study reported a hazard ratio of 0.41.
• Median progression-free survival reached 11.5 months.
• Patients receiving R-GemOx recorded a median progression-free survival of 3.8 months.
• Safety findings were consistent with the known profiles of the individual medicines.

The results suggest that the combination could offer a meaningful improvement for patients whose disease returns or does not respond to previous treatment.

Also Read: Scaling Perfusion Technology from Lab Success to Manufacturing Reality

Roche Targets Major Unmet Need in Lymphoma Care

According to Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, relapsed or refractory large B-cell lymphoma remains one of the most challenging areas in lymphoma treatment.

He said that, if approved, the Lunsumio VELO and Polivy combination could provide an important chemotherapy-free option that is suitable for outpatient use and may help improve patient outcomes.

Clinical experts also emphasized the need for more accessible therapies. Tara M. Graff, Director of Clinical Research at Mission Cancer and Blood, noted that second-line treatment represents a critical period for patients with large B-cell lymphoma. She highlighted that many advanced therapies come with logistical and geographic challenges, particularly because most US patients receive treatment in community settings rather than large academic centers.

Expanding Access for Patients Closer to Home

Patient advocates believe the combination could improve access to care for people living far from specialized treatment centers.

Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation, said patients with relapsed or refractory large B-cell lymphoma often face difficulties accessing advanced treatment options. She added that the potential approval of Lunsumio VELO and Polivy could help patients receive treatment closer to where they live, reducing travel burdens and improving access to care.

Why This Matters

• LBCL, primarily diffuse large B-cell lymphoma, is the most common form of non-Hodgkin lymphoma in the US.
• More than 18,000 new cases are diagnosed annually.
• Up to 40% of patients relapse or become refractory after frontline treatment.
• Outcomes often worsen rapidly once the disease returns due to limited treatment options.

Lunsumio is part of Roche’s CD20xCD3 bispecific antibody program and is designed for flexible administration in both intravenous and subcutaneous forms. Both Lunsumio IV and Lunsumio VELO are already approved for third-line or later follicular lymphoma.

Roche is also expanding the program through ongoing Phase III studies, including CELESTIMO and MorningLyte, which are evaluating the treatment in earlier stages of follicular lymphoma care.